Laval, Québec, CANADA – December 1st, 2011 – Neptune Technologies & Bioressources Inc. (“Neptune”) (NASDAQ.NEPT - TSX.NTB) today provided revenue guidance for the third quarter of Fiscal 2012 ended November 30th.

Neptune Preliminary Revenues
Neptune management is confident  that third quarter revenues will be in the range of $5,000,000 to $5,250,000 compared to $4,290,000 for the third quarter ended November 30, 2010, representing an increase of 17% to 22%.

“This is a record quarter for us. A solid foundation has been established by our American distributors and we are now beginning to see the results of our mass roll out in the United States,” said Andre Godin CFO of Neptune Technologies & Bioressources. “American consumers can now find Neptune’s products on the shelves of stores such as Wal-Mart, Walgreens and others. 

“We are receiving a very positive response from US consumers,” said Michel Timperio, VP Business Development of Neptune Technologies & Bioressources. “Based on growing interest and consumer education on the benefits of Krill oil, we are confident Neptune will see strong continued growth in the US market in coming quarters.”


About Neptune Technologies & Bioressources Inc.

Neptune is an industry-recognized leader in the innovation, production and formulation of science-based and clinically proven novel phospholipid products for the nutraceutical and pharmaceutical markets. The Company focuses on growing consumer health markets including cardiovascular, inflammatory and neurological diseases driven by consumers taking a more proactive approach to managing health and preventing disease. The Company sponsors clinical trials aimed to demonstrate its product health benefits and to obtain regulatory approval for label health claims. Neptune is continuously expanding its intellectual property portfolio as well as clinical studies and regulatory approvals. Neptune’s products are marketed and distributed in over 20 countries worldwide.

Acasti Pharma (TSXV: APO) is developing a product portfolio of proprietary novel long-chain omega-3 phospholipids. Phospholipids are the major component of cell membranes and are essential for all vital cell processes. They are one of the principal constituents of High Density Lipoprotein (good cholesterol) and, as such, play an important role in modulating cholesterol efflux. Acasti Pharma’s proprietary novel phospholipids carry and functionalize the polyunsaturated omega-3 fatty acids EPA and DHA, which have been shown to have substantial health benefits and which are stabilized by astaxanthin, a potent antioxidant. Acasti Pharma is focusing initially on treatments for chronic cardiovascular and cardiometabolic conditions within the over-the-counter, medical food and prescription drug markets.

NeuroBioPharm is pursuing pharmaceutical neurological applications, and a clinical study for a medical food product with a multinational partner is already initiated. The development of a prescription drug candidate is currently in progress. Advanced clinical development and commercialization is planned to be carried out with multinational partners.